Gsk (GSK) Current Taxes (2009 - 2026)

Gsk (GSK) has 18 years of Current Taxes data on file, last reported at -$703.0 million in Q2 2026.

• For the quarter ending Q2 2026, Current Taxes rose 9.29% year-over-year to -$703.0 million; the trailing twelve-month figure through Jun 2026 stood at -$703.0 million (up 9.29% YoY), and the FY2025 full-year result was -$662.4 million, up 26.29% from the prior year.
• Current Taxes was -$703.0 million for Q2 2026 at Gsk, up from -$748.2 million in the prior quarter.
• In the past five years, Current Taxes ranged from a high of -$152.0 million in Q3 2022 to a low of -$922.7 million in Q2 2024.
• A 5-year average of -$620.7 million and a median of -$671.6 million in 2023 frame the typical range for Current Taxes.
• Across the five-year window, Current Taxes surged 84.62% in 2022 and slumped 138.29% in 2023, its largest moves.
• Gsk's Current Taxes stood at -$552.4 million in 2022, then slipped by 12.33% to -$620.6 million in 2023, then sank by 45.4% to -$902.3 million in 2024, then rose by 26.59% to -$662.4 million in 2025, then retreated by 6.13% to -$703.0 million in 2026.
• Per Business Quant data, the three most recent Current Taxes figures were -$703.0 million in Q2 2026, -$748.2 million in Q1 2026, and -$662.4 million in Q4 2025.